Compounds > topotecan

Page last updated: 2024-08-24

topotecan and decitabine

topotecan has been researched along with decitabine in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (16.67)	18.2507
2000's	4 (66.67)	29.6817
2010's	1 (16.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Lombardo, F; Obach, RS; Waters, NJ	1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Abbruzzese, JL; Anzai, H; Frost, P	1
Avula, R; Bible, KC; Hartmann, LC; Huang, H; Kalli, K; Kaufmann, SH; Lee, YK; Shridhar, V; Smith, DI; Staub, J	1
Karp, J	1

Reviews

1 review(s) available for topotecan and decitabine

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Other Studies

5 other study(ies) available for topotecan and decitabine

Article	Year
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Physicochemical determinants of human renal clearance. Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15 Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight	2009
Synergistic cytotoxicity with 2'-deoxy-5-azacytidine and topotecan in vitro and in vivo. Cancer research, 1992, Apr-15, Volume: 52, Issue:8 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Azacitidine; Camptothecin; Colorectal Neoplasms; Decitabine; DNA Topoisomerases, Type I; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Female; Lethal Dose 50; Methylation; Mice; Mice, Inbred BALB C; Topotecan; Tumor Cells, Cultured	1992
Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer. Cancer research, 2001, May-15, Volume: 61, Issue:10 Topics: Amino Acid Sequence; Azacitidine; Base Sequence; Chromosome Mapping; Cisplatin; Cloning, Molecular; Decitabine; DNA, Neoplasm; Down-Regulation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Heat-Shock Proteins; HSP40 Heat-Shock Proteins; Humans; In Situ Hybridization, Fluorescence; Loss of Heterozygosity; Molecular Sequence Data; Ovarian Neoplasms; Oximes; Paclitaxel; Piperazines; Reverse Transcriptase Polymerase Chain Reaction; Sequence Homology, Amino Acid; Topotecan; Transfection; Tumor Cells, Cultured	2001
Future research directions for the treatment of AML. Clinical advances in hematology & oncology : H&O, 2008, Volume: 6, Issue:11 Topics: Antineoplastic Agents; Azacitidine; Biomedical Research; Carbazoles; Carboplatin; Cytarabine; Daunorubicin; Decitabine; Enzyme Inhibitors; Etoposide; Flavonoids; Furans; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Piperidines; Quinolones; Staurosporine; Topotecan; Tretinoin	2008